Agreed one constant poster who can’t help but be hateful and lewd. Here’s what is decided, all pain drugs can and will be forfeited by end of year. They go back to the original company. That’s Movantik and bonds. LPI will continue with INJ but total reps will be reduced but number is not decided. Very few of pain reps will be kept maybe a few for QUIZ but Japan is not supportive of this and wants out of stigma of pain drugs. 8201 will be partnered commercially, looks like Genentech but Novartis is possible. DSI would lead development but other company does commercial and sales. We could have sales there but very small and 8201 is very far away. Most internal functions supporting sales will be outsourced, dramatically cut or reduced. Some will survive but very few maybe 20%. You should know the lead attorney, head of sales and marketing, head of access, three RD heads and head of HR all left on their own so you ha e to ask what do they know. I assume they know it’s really bad took a big severance and left. If you stay you roll the dice so you should at least be exploring options. Japan does not believe we can sell in cancer. I’m here but actively looking as any change is not likely to be announced until October or maybe January. Good luck with things